MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-27-2025
OrganiGram Holdings Retained Earnings 2011-2025 | OGI
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -145 M | -8.78 M | 759 K | -19.8 M | -8.87 M | -9.71 M | -833 K | -594 K | -219 K | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 759 K | -145 M | -21.4 M |
Quarterly Retained Earnings OrganiGram Holdings
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -276 M | - | - | - | -145 M | - | - | - | -8.78 M | - | - | - | 759 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 759 K | -276 M | -107 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.21 | 1.68 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.67 | 0.19 % | $ 1.39 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 4.35 | -3.12 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.29 | -1.09 % | $ 629 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.57 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 6.66 | -3.55 % | $ 413 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 50.7 | 1.22 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.27 | -1.32 % | $ 22.2 M |  China |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 5.19 | -1.71 % | $ 683 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 7.16 | -0.56 % | $ 2.61 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.66 | 0.83 % | $ 4.54 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.01 | -2.55 % | $ 56.4 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.8 | -7.01 % | $ 18.7 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.17 | -1.3 % | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.71 | -1.16 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.22 | -7.71 % | $ 299 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 13.94 | 0.87 % | $ 1.92 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.45 | -14.17 % | $ 7.13 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.43 | -15.88 % | $ 6.17 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.43 | -1.77 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 9.56 | -3.82 % | $ 679 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.63 | -3.68 % | $ 230 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.63 | 6.75 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 9.32 | -2.87 % | $ 5.76 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.68 | -3.43 % | $ 17.5 M | USA |